Attovia Therapeutics (ATTO) Q2 2026 earnings summary

Executive summary

• Clinical-stage biopharma focused on immune-mediated diseases, with three internally discovered candidates: ATTO-1310 (completed Phase 1 dosing and clinical proof of concept in chronic pruritus and high-itch atopic dermatitis; full data expected Q4 2026), ATTO-2306, and ATTO-1091 in IND-enabling studies, both expected to enter Phase 1 in 2027.

• Net loss for the six months ended June 30, 2026 was $39.3 million, up from $29.6 million year-over-year; accumulated deficit reached $150.4 million.

• Completed IPO in August 2026, raising $332.4 million in gross proceeds ($305.4 million net), extending cash runway into 2030.

Financial highlights

• Revenue of $0.5 million for the six months ended June 30, 2026, from collaboration with EndPath; no product sales revenue.

• Research and development expenses rose 40% year-over-year to $35.7 million for the first half of 2026; Q2 2026 R&D expenses were $18.9 million, up from $13.6 million in Q2 2025.

• General and administrative expenses decreased 10% to $6.5 million for the first half of 2026, but Q2 2026 G&A expenses increased slightly to $3.3 million from $3.0 million year-over-year.

• Cash, cash equivalents, and marketable securities totaled $115.1 million as of June 30, 2026, prior to IPO proceeds, down from $152.3 million at year-end 2025.

Outlook and guidance

• Existing cash, cash equivalents, marketable securities, and IPO proceeds expected to fund operations into 2030.

• Plans to initiate Phase 2 studies for ATTO-1310 in chronic pruritus and high-itch AD, and Phase 1 trials for ATTO-2306 and ATTO-1091 in the first half of 2027.

• Early-stage pipeline candidate ATTO-006 expected to reach development nomination by year-end 2026.

• Anticipates significant increases in R&D and operational expenses as pipeline advances and organization scales.